Rosiglitazone Maleate__Insulin sensitizer Omecamtiv mecarbil
Product Name
Rosiglitazone Maleate
Description
Insulin sensitizer
Purity
>98%
CAS No.
155141-29-0
Molecular Formula
C18H19N3O3S•C4H4O4
Molecular Weight
473.5
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Agonist
Solubility
Soluble in DMSO (3 mg/ml) or DMF (10 mg/ml)
Source
Synthetic
Appearance
White to off-white solid
SMILES
C2=C(CC1SC(=O)NC1=O)C=CC(=C2)OCCN(C3=CC=CC=N3)C.O=C(O)C=C/C(=O)O
InChI
InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
InChIKey
YASAKCUCGLMORW-UHFFFAOYSA-N
Safety Phrases
Classification: Caution: Substance not yet fully tested.
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Cite This Product
Rosiglitazone Maleate (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-379)
Alternative Names
5-4-2-(Methyl-2-pyridinylamino)ethoxyphenylmethyl-2,4-thiazolidinedione
Research Areas
Cell Signaling
PubChem ID
77999
Scientific Background
Rosiglitazone is a potent agonist for PPARγ with an EC50 of 43 nM for the human receptor. It is anti-diabetic, working as an insulin sensitizer by binding to the PPARγ receptors in fat cells and making the cells more responsive to insulin.
References
1. Werner A.L., & Travaglini M.T. (2001) Pharmacotherapy. 21(9): 1082-99.
2. McMorran M., and Vu D. (2001) CMAJ. 165(1): 82-3, 86-7.
3. Malinowski J.M. & Bolesta S. (2000) Clin. Ther. 22(10): 1151-68.
4. Cheng-Lai A., & Levine A. (2000) Heart Dis. 2(4): 326-33.
5. Knock G.A., et al. (1999) Eur. J. Pharmacol. 368(1): 103-9.
6. Balfour J.A., & Plosker G.L. (1999) Drugs. 57(6): 921-30.
7. Parks D.J., et al. (1998) Bioorg. Med. Chem. Lett. 8(24): 3657-8.
Insulin sensitizer
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
2. McMorran M., and Vu D. (2001) CMAJ. 165(1): 82-3, 86-7.
3. Malinowski J.M. & Bolesta S. (2000) Clin. Ther. 22(10): 1151-68.
4. Cheng-Lai A., & Levine A. (2000) Heart Dis. 2(4): 326-33.
5. Knock G.A., et al. (1999) Eur. J. Pharmacol. 368(1): 103-9.
6. Balfour J.A., & Plosker G.L. (1999) Drugs. 57(6): 921-30.
7. Parks D.J., et al. (1998) Bioorg. Med. Chem. Lett. 8(24): 3657-8.